JPRN-jRCTs061210065招募中3 期
Efficacy and safety of Combination therapy of Hepatic Arterial Infusion Chemotherapy and Atezolizumab with Bevacizumab for patients with unresectable advanced Hepatocellular Carcinoma
Takeuchi Yasuto0 个研究点目标入组 100 人开始时间: 2021年12月17日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1 20 age old over
- •2 Regardless of gender
- •3 Less than 1 of performance status
- •4 Patients who diagnosed with unresectable advanced Hepatocellular Carcinoma
- •5 Patients who have no treatment history of HAIC with Cisplatin
- •6 Patients who are getting treatment with Atezolizumab plus Bevacizumab
- •7 Measurable tumors in the liver
- •8 Patienst who have been fully informed consent
排除标准
- •1 Patients with Child-Pugh score of 8 points or more
- •2 Allergy for contrast media
- •3 Less than 30 mL/min of eGFR
- •4 Allergy for Cisplatin
- •5 Allergy for Atezolizumab
- •6 Allergy for Bevacizumab
- •7 History of Hemoptysis
- •8 History of autoimmune disease
- •9 Interstitial pneumonia
- •10 Intraperitoneal inflamation or wounded
- •11 Brain metastasis
- •12 Congenital hemorrhagic disease
- •13 Severe Hart failure
- •14 Being pregnant or possibly pregnant
- •15 Patients who judged as inappropriate candidate by the chief medical examine
研究者
相似试验
招募中
不适用
Study of TAE added on chemotherapy in patients with metastatic neuroendocrine tumorsGastroenteropancreatic neuroendocrine neoplasmsJPRN-jRCT1061210015Kato Hironari18
已完成
不适用
Efficacy and safety of hybrid therapy combined with branched-chain amino acid and resistance training in frail patients with cardiovascular diseasefrail patients with cardiovascular diseaseJPRN-UMIN000034714Sakakibara Heart Institute90
已完成
不适用
Efficacy and safety of hybrid therapy combined with branched-chain amino acid and resistance training in frail CKD patients with cardiovascular diseasefrail CKD patients with cardiovascular diseaseJPRN-UMIN000034733Department of Rehabilitation, Sakakibara Heart institute90
进行中（未招募）
不适用
COMET TrialJPRN-jRCTs031180210Yokote Koutaro60
已完成
不适用
Effectiveness and safety of Combination therapy of Ranibizumab and LuseOgliflozin in type 2 diabetes with diabetic Macular Edema, a parallel group comparison with the standard Treatment controlled by Glimepiride, multicenter, randomized, open-label trial. (COMET Trial)JPRN-UMIN000033961Chiba University60